IN8bio price target lowered to $8 from $12.50 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on IN8bio (INAB) to $8 from $12.50 and keeps a Buy rating on the shares post the Q3 report. The company is implementing strategies to de-risk INB-100 ahead of the registrational study, the analyst tells investors in a research note.